A number of research firms have recently commented on QCOR. Analysts at Oppenheimer raised their price target on shares of Questcor Pharmaceuticals from $57.00 to $73.00 in a research note to investors on Monday. They now have an “outperform” rating on the stock. Separately, analysts at Lazard Capital Markets set a $85.00 price target on shares of Questcor Pharmaceuticals in a research note to investors on Thursday. They now have a "buy" rating on the stock. Finally, analysts at Mizuho raised their price target on shares of Questcor Pharmaceuticals from $65.00 to $84.00 in a research note to investors on Monday, August 12th. They now have a “buy” rating on the stock.
Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $63.51. NOTE FROM MAXDAD...RIDICULOUS---RIDICULOUS---RIDICULOUS.....$100 BY EOY!!!
Questcor Pharmaceuticals (NASDAQ:QCOR) traded up 1.94% on Monday, hitting $66.59. 157,507 shares of the company’s stock traded hands. Questcor Pharmaceuticals has a 1-year low of $17.25 and a 1-year high of $70.55. The stock has a 50-day moving average of $54.54 and a 200-day moving average of $38.55. The company has a market cap of $3.925 billion and a P/E ratio of 17.53.
Questcor Pharmaceuticals (NASDAQ:QCOR) last announced its earnings results on Tuesday, July 30th. The company reported $1.12 earnings per share (EPS) for the quarter (GAAP---NON GAAP $1.32, beating the consensus estimate of $0.96 by $0.16. The company had revenue of $184.60 million for the quarter, compared to the consensus estimate of $168.96 million. During the same quarter in the previous year, the company posted $0.65 earnings per share. The company’s revenue for the quarter was up 64.1% on a year-over-year basis. On average, analysts predict that Questcor Pharmaceuticals will post $4.81 earnings per share for the current fiscal year.